Advanced Search

 

Study ID Status Title Patient Level Data
201431 Not yet recruiting Adherence to Dabrafenib plus Trametinib in subjects with BRAF V600 mutant unresectable or metastatic melanoma
201435 Completed A randomised, multi-centre, open label, cross-over non-inferiority study to evaluate efficacy, safety and tolerability of Neumoterol 400 and Symbicort Forte in adults with asthma
201436 Recruiting A Randomized, Open-label Study to Evaluate the Immunogenicity of Anthrax Vaccine Adsorbed Alone or Concomitantly with Raxibacumab (GSK3068483)
201450 Not yet recruiting ENCRUSE ELLIPTA Drug Use Investigation
201461 Withdrawn A Randomised, Two Treatment, Four-Way Cross-Over (Replicate Design), Two Sequence, Repeat Dose Study in Patients with Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered via the Low Airflow Resistance Fluticasone Propionate/Salmeterol (100/50 mcg) ROTAHALER Inhaler Relative to Fluticasone Propionate/Salmeterol (100/50 mcg) Delivered via the DISKUS Inhaler
201463 Completed Measurement of neutrophil retention in the lung in vivo, using autologous labelled neutrophils, in healthy subjects following lipopolysaccharide or saline challenge and patients with chronic obstructive pulmonary disease (COPD)
201464 Not yet recruiting A multiple treatment session, open label phase 2 clinical study of GSK2398852 administered following and together with GSK2315698 in cohorts of patients with cardiac amyloidosis
201465 Completed A Phase I Trial to Evaluate Safety and Efficacy of Topically Applied GSK2981278 Ointment in a Psoriasis Plaque Test
201474 Completed A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and Mometasone Furoate Nasal Spray in Subjects with Allergic Rhinitis
201476 Active not recruiting Fluarix®/ FluLaval®/ Fluarix® Quadrivalent/ FluLaval® Quadrivalent Pregnancy Registry: a prospective, exploratory, cohort study to detect and describe abnormal pregnancy outcomes in women intentionally or unintentionally vaccinated with Fluarix® or Fluarix® Quadrivalent or FluLaval® or FluLaval® Quadrivalent during pregnancy or within 28 days preceding conception.
201477 Completed Duration of Protection Following Five Doses of GlaxoSmithKline’s (GSK’s) DTaP Vaccines in School Age Children
201479 Completed A Phase I Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 in Subjects with Hepatic Impairment and Healthy Matched Control Subjects
201480 Completed A Phase I, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 in Subjects with Severe Renal Impairment and Healthy Matched Control Subjects
201484 Completed A Phase 2a Study to Evaluate the Clinical Effect, Pharmacokinetics, Safety and Tolerability of Topically Applied Umeclidinium in Subjects with Primary Palmar Hyperhidrosis
201486 Completed PGX6475: PGx evaluation of HLA alleles with rash in lapatinib treated patients from TEACH (EGF105485)
201490 Completed PGx7591: Pharmacogenetic Evaluation of HLA effect on safety events in systemic lupus erythematosus patients treated with GSK2586184 in study JAK115919
201491 Not yet recruiting Observational retrospective cohort study, comparing outcomes in Salford, UK (data source: SLS) with rest of UK (data source: CPRD) over a 12 month period
201492 Recruiting A Randomized, Doubled-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of Fluticasone Furoate Nasal Spray 55 mcg and 110 mcg for 4 Weeks in Chinese Pediatric Subjects Ages 2 to 12 Years with Allergic Rhinitis
201496 Completed 201496: A Study to Evaluate the Efficacy and Safety of 15mg BID Losmapimod (GW856553) Compared to Placebo in Frequently Exacerbating Subjects with Chronic Obstructive Pulmonary Disease (COPD)
201499 Active not recruiting A randomised, placebo-controlled, double-blind, two period crossover study to characterise the exhaled nitric oxide time profile as a biomarker of airway inflammation in adult asthma patients following repeat administration of inhaled Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 mcg.
201510 Completed An observer-blind study to assess the safety, reactogenicity and immunogenicity of different formulations of GSK Biologicals’ investigational RSV vaccine (GSK3003891A), in healthy women
201512 Active not recruiting Clinical and economic outcomes associated with use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium as initial maintenance treatment for chronic obstructive pulmonary disease in a managed care setting
201514 Active not recruiting Impact of initiating maintenance treatment (MT) promptly post-chronic obstructive pulmonary disease (COPD) exacerbation in a managed care setting
201521 Recruiting Impact of Boostrix™ maternal vaccination on morbidity and mortality of pertussis disease in infants ≤6 weeks of age, in Bogota, Colombia.
201527 Completed Comparative Randomized, Single dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Rabeprazole from Idiazole 20mg DR tabs (GSK, Egypt)and PARIET 20 mg DR tabs (JANSSEN, EGYPT) after a Single Oral Dose Administration of each to Healthy Adults under Fasting Conditions

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.